Eudaimonia Partners’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Eudaimonia Partners’s Portfolio BBC Stock Details BBC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-382	Closed	-$20K	–	456
2021 Q1	$20K	Buy	+382	New	+$20.9K	﹤0.01%	934

Other funds holding BBC

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Flow Traders U.S. New York $2.43B AUM 44.44% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Eudaimonia Partners's BBC Position: Q2 2021 in Review

Eudaimonia Partners sold out of Virtus Biotech Clinical Trials ETF (BBC) in Q2 2021, closing a stake of 382 shares — an estimated $20K sold.

Eudaimonia Partners first reported a position in BBC in Q1 2021 and held it in 1 quarter. The position peaked at $20K in Q1 2021. 19 funds tracked by Wall St. Rank hold BBC as of Q2 2021.

Eudaimonia Partners reported no remaining Virtus Biotech Clinical Trials ETF position as of Q2 2021 after selling out during the quarter.
Eudaimonia Partners sold 382 Virtus Biotech Clinical Trials ETF shares in Q2 2021, an estimated $20K.
Eudaimonia Partners first reported a position in Virtus Biotech Clinical Trials ETF in Q1 2021 and held it in 1 quarter.
Eudaimonia Partners's Virtus Biotech Clinical Trials ETF position peaked at $20K in Q1 2021.
19 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.